Literature DB >> 25838394

Intratumoral Heterogeneity: From Diversity Comes Resistance.

Ariel Pribluda1, Cecile C de la Cruz1, Erica L Jackson2.   

Abstract

Tumors consist of a heterogeneous mixture of functionally distinct cancer cells. These functional differences can be caused by varying levels of receptor activity, differentiation, and distinct metabolic and epigenetic states. Intratumoral heterogeneity can lead to interdependence among different subpopulations of cells for sustained tumor growth. In addition, subpopulations can vary widely in their responses to therapeutic agents. As such, it is believed that intratumoral heterogeneity may underlie incomplete treatment responses, acquired and innate resistance, and disease relapse observed in the clinic in response to conventional chemotherapy and targeted agents. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 25838394     DOI: 10.1158/1078-0432.CCR-14-1213

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  59 in total

1.  Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trial.

Authors:  Naser Davarzani; Lindsay C Hewitt; Matthew D Hale; Veerle Melotte; Matthew Nankivell; Gordon G A Hutchins; David Cunningham; William H Allum; Ruth E Langley; Shahab Jolani; Heike I Grabsch
Journal:  Dis Esophagus       Date:  2020-08-03       Impact factor: 3.429

Review 2.  Pyruvate and Metabolic Flexibility: Illuminating a Path Toward Selective Cancer Therapies.

Authors:  Kristofor A Olson; John C Schell; Jared Rutter
Journal:  Trends Biochem Sci       Date:  2016-02-10       Impact factor: 13.807

3.  HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.

Authors:  Simona di Martino; Carla Azzurra Amoreo; Barbara Nuvoli; Rossella Galati; Sabrina Strano; Francesco Facciolo; Gabriele Alessandrini; Harvey I Pass; Gennaro Ciliberto; Giovanni Blandino; Ruggero De Maria; Mario Cioce
Journal:  Oncogene       Date:  2018-01-09       Impact factor: 9.867

Review 4.  Heralding a new paradigm in 3D tumor modeling.

Authors:  Eliza L S Fong; Daniel A Harrington; Mary C Farach-Carson; Hanry Yu
Journal:  Biomaterials       Date:  2016-09-02       Impact factor: 12.479

5.  Evaluation of radiation-related invasion in primary patient-derived glioma cells and validation with established cell lines: impact of different radiation qualities with differing LET.

Authors:  M Wank; D Schilling; J Reindl; B Meyer; J Gempt; S Motov; F Alexander; J J Wilkens; J Schlegel; T E Schmid; S E Combs
Journal:  J Neurooncol       Date:  2018-06-08       Impact factor: 4.130

6.  Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers.

Authors:  Alba Mota; Eva Colás; Pablo García-Sanz; Irene Campoy; Alejandro Rojo-Sebastián; Sonia Gatius; Ángel García; Luis Chiva; Sonsoles Alonso; Antonio Gil-Moreno; Xavier González-Tallada; Berta Díaz-Feijoo; August Vidal; Patrycja Ziober-Malinowska; Marcin Bobiński; Rafael López-López; Miguel Abal; Jaume Reventós; Xavier Matias-Guiu; Gema Moreno-Bueno
Journal:  Mod Pathol       Date:  2016-09-02       Impact factor: 7.842

7.  Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.

Authors:  Christina Blassl; Jan Dominik Kuhlmann; Alessandra Webers; Pauline Wimberger; Tanja Fehm; Hans Neubauer
Journal:  Mol Oncol       Date:  2016-04-20       Impact factor: 6.603

8.  Effective quality management practices in routine clinical next-generation sequencing.

Authors:  Francine B de Abreu; Jason D Peterson; Christopher I Amos; Wendy A Wells; Gregory J Tsongalis
Journal:  Clin Chem Lab Med       Date:  2016-05       Impact factor: 3.694

9.  Prognostic Impact of Intratumoral Heterogeneity Based on Fractal Geometry Analysis in Operated NSCLC Patients.

Authors:  Angelo Castello; Carlo Russo; Fabio Grizzi; Dorina Qehajaj; Egesta Lopci
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

10.  Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells.

Authors:  Pan-Yu Chen; Mandar Deepak Muzumdar; Kimberly Judith Dorans; Rebecca Robbins; Arjun Bhutkar; Amanda Del Rosario; Philipp Mertins; Jana Qiao; Anette Claudia Schafer; Frank Gertler; Steven Carr; Tyler Jacks
Journal:  Cancer Res       Date:  2017-12-26       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.